WHO classification of myeloproliferative neoplasms (MPN): A critical update

Current Hematologic Malignancy Reports

Volumn 8, Issue 4, 2013, Pages 333-341

  Kvasnicka, Hans Michael ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Bone marrow histology; Early prefibrotic PMF; Essential thrombocythemia; Hematologic malignancy; Polycythemia vera; Primary myelofibrosis; WHO classification

Indexed keywords

ACETYLSALICYLIC ACID; JANUS KINASE 2; LACTATE DEHYDROGENASE; RETICULIN;

ARTICLE; BONE MARROW BIOPSY; CANCER SURVIVAL; DISEASE CLASSIFICATION; ERYTHROBLAST; EVENT FREE SURVIVAL; GRANULOPOIESIS; HISTOPATHOLOGY; HUMAN; MEGAKARYOCYTE; MEGAKARYOPOIESIS; MYELOBLAST; MYELODYSPLASTIC SYNDROME; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; OSTEOSCLEROSIS; OVERALL SURVIVAL; POLYCYTHEMIA VERA; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; SPLENOMEGALY; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOCYTOSIS; WORLD HEALTH ORGANIZATION;

DIAGNOSIS, DIFFERENTIAL; HEMATOLOGIC NEOPLASMS; HUMANS; POLYCYTHEMIA; PRIMARY MYELOFIBROSIS; REPRODUCIBILITY OF RESULTS; THROMBOCYTHEMIA, ESSENTIAL; WORLD HEALTH ORGANIZATION;

EID: 84890548359     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-013-0186-x     Document Type: Article

References (99)

1. Swerdlow S, Campo E, Harris N, et al. WHO classification of tumours of haematopoietic and lympoid tissues Lyon. France: IARC Press; 2008.
2. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110:1092-7.
3. Spivak JL, Silver RT. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. Blood. 2008;112:231-9.
4. Campbell PJ, Bareford D, Erber WN, et al. Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. J Clin Oncol. 2009;27:2991-9.
5. Wilkins BS, Erber WN, Bareford D, et al. Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood. 2008;111:60-70.
6. Rüdiger T, Weisenburger DD, Anderson JR, et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. Ann Oncol. 2002;13:140-9.
7. Lones MA, Auperin A, Raphael M, et al. Mature B-cell lymphoma/leukemia in children and adolescents: intergroup pathologist consensus with the revised European-American Lymphoma Classification. Ann Oncol. 2000;11:47-51.
8. Glaser SL, Dorfman RF, Clarke CA. Expert review of the diagnosis and histologic classification of Hodgkin disease in a population-based cancer registry: interobserver reliability and impact on incidence and survival rates. Cancer. 2001;92:218-24.
9. Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study of 1,104 patients. J Clin Oncol. 2011;29:3179-84. An important multicenter study that highlighted the clinical impact of WHO diagnostic criteria.
10. Thiele J, Kvasnicka HM, Mullauer L, et al. Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. Blood. 2011;117:5710-8. A multicenter trial that underscored the prognostic impact of the WHO guidelines with regard to early/prefibrotic PMF.
11. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937-51.
12. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22:14-22.
13. Kvasnicka HM, Thiele J. Classification of Ph-negative chronic myeloproliferative disorders-morphology as the yardstick of classification. Pathobiology. 2007;74:63-71.
14. Kvasnicka HM, Thiele J. Prodromal myeloproliferative neoplasms: the 2008 WHO classification. Am J Hematol. 2010;85:62-9. A very comprehensive review that summarized the problems of prodromal MPN.
15. Thiele J, Kvasnicka HM, Diehl V. Standardization of bone marrow features - does it work in hematopathology for histological discrimination of different disease patterns? Histol Histopathol. 2005;20:633-44.
16. Thiele J, Kvasnicka HM. Diagnostic differentiation of essential thrombocythaemia from thrombocythaemias associated with chronic idiopathic myelofibrosis by discriminate analysis of bone marrow features-a clinicopathological study on 272 patients. Histol Histopathol. 2003;18:93-102.
17. Barbui T, Thiele J, Vannucchi AM, et al. Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia. Leukemia. 2013. doi: 10.1038/leu.2013.74. A comprehensive survey about the current problems of the WHO criteria for the diagnosis of early stage PMF.
18. Thiele J, Kvasnicka HM, Orazi A. Bone marrow histopathology in myeloproliferative disorders - current diagnostic approach. Semin Hematol. 2005;42:184-95.
19. Thiele J, Kvasnicka HM. A critical reappraisal of the WHO classification of the chronic myeloproliferative disorders. Leuk Lymphoma. 2006;47:381-96.
20. Thiele J, Kvasnicka HM, Vardiman J. Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders: a forgotten pearl. Best Pract Res Clin Haematol. 2006;19:413-37.
21. Thiele J, Kvasnicka HM, Facchetti F, et al. European consensus for grading of bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90:1128-32.
22. Kuter DJ, Bain B, Mufti G, et al. Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. Br J Haematol. 2007;139:351-62.
23. Thiele J, Kvasnicka HM. Myelofibrosis-what's in a name? Consensus on definition and EUMNET grading. Pathobiology. 2007;74:89-96.
24. Thiele J, Kvasnicka HM. Hematopathologic findings in chronic idiopathic myelofibrosis. Semin Oncol. 2005;32:380-94.
25. Thiele J, Kvasnicka HM. Grade of bone marrow fibrosis is associated with relevant hematological findings-a clinicopathological study on 865 patients with chronic idiopathic myelofibrosis. Ann Hematol. 2006;85:226-32.
26. Thiele J, Kvasnicka HM. Myelofibrosis in chronic myeloproliferative disorders-dynamics and clinical impact. Histol Histopathol. 2006;21:1367-78.
27. Gianelli U, Vener C, Bossi A, et al. The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis. Mod Pathol. 2012;25:1193-202. An important paper that underscores the impact of bone marrow fibrosis as prognostic marker in PMF.
28. Vener C, Fracchiolla NS, Gianelli U, et al. Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis. Blood. 2008;111:1862-5.
29. Thiele J, Kvasnicka HM. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients. Ann Hematol. 2003;82:148-52.
30. Brousseau M, Parot-Schinkel E, Moles MP, et al. Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis. Histopathology. 2010;56:758-67.
31. Buhr T, Hebeda K, Kaloutsi V, et al. European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica. 2012;97:360-5.
32. Florena AM, Tripodo C, Iannitto E, et al. Value of bone marrow biopsy in the diagnosis of essential thrombocythemia. Haematologica. 2004;89:911-9.
33. Kreft A, Buesche G, Ghalibafian M, et al. The incidence of myelofibrosis in essential thrombocythaemia, polycythaemia vera and chronic idiopathic myelofibrosis: a retrospective evaluation of sequential bone marrow biopsies. Acta Haematol. 2005;113:137-43.
34. Gianelli U, Iurlo A, Vener C, et al. The significance of bone marrow biopsy and JAK2V617F mutation in the differential diagnosis between the "early" prepolycythemic phase of polycythemia vera and essential thrombocythemia. Am J Clin Pathol. 2008;130:336-42.
35. Gianelli U, Vener C, Raviele PR, et al. Essential thrombocythemia or chronic idiopathic myelofibrosis? A single-center study based on hematopoietic bone marrow histology. Leuk Lymphoma. 2006;47:1774-81.
36. Boiocchi L, Mathew S, Gianelli U, et al. Morphologic and cytogenetic differences between post-polycythemic myelofibrosis and primary myelofibrosis in fibrotic stage. Mod Pathol. 2013.
37. Diebold J, Anderson JR, Armitage JO, et al. Diffuse large B-cell lymphoma: a clinicopathologic analysis of 444 cases classified according to the updated Kiel classification. Leuk Lymphoma. 2002;43:97-104.
38. Mufti GJ, Bennett JM, Goasguen J, et al. Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica. 2008;93:1712-7.
39. Murphy S, Peterson P, Iland H, et al. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol. 1997;34:29-39.
40. Pearson TC. Diagnosis and classification of erythrocytoses and thrombocytoses. Baillieres Clin Haematol. 1998;11:695-720.
41. Murphy S. Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia. Semin Hematol. 1999;36:9-13.
42. Harrison CN, Bareford D, Butt N, et al. Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br J Haematol. 2010;149:352-75.
43. Thiele J, Kvasnicka HM, Schmitt-Graeff A, et al. Follow-up examinations including sequential bone marrow biopsies in essential thrombocythemia (ET): a retrospective clinicopathological study of 120 patients. Am J Hematol. 2002;70:283-91.
44. Thiele J, Kvasnicka HM, Schmitt-Gräff A, et al. Dynamics of fibrosis in chronic idiopathic (primary) myelofibrosis during therapy: a follow-up study on 309 patients. Leuk Lymphoma. 2003;44:549-53.
45. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353:33-45.
46. Thiele J, Kvasnicka HM, Vardiman JW, et al. Bone marrow fibrosis and diagnosis of essential thrombocythemia. J Clin Oncol. 2009;27:e220-1. author reply e222-223.
47. Thiele J, Orazi A, Kvasnicka HM, et al. European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica. 2012;97(3):360-5. - comment. Haematologica 2012, 97:e5-6; discussion e7-8.
48. Madelung AB, Bondo H, Stamp I, et al. WHO-defined classification of myeloproliferative neoplasms: morphological reproducibility and clinical correlations - the Danish experience. Am J Hematol. 2013. doi: 10.1002/ajh.23554. In this study interobserver and intraobserver reproducibility and concordance between histological diagnosis and independently collected clinical findings in a large series of patients with the major subtypes of MPN and controls were examined.
49. Tefferi A, Skoda R, Vardiman JW. Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics. Nat Rev Clin Oncol. 2009;6:627-37.
50. Tefferi A, Thiele J, Vardiman JW. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer. 2009.
51. Tefferi A, Vardiman JW. The diagnostic interface between histology and molecular tests in myeloproliferative disorders. Curr Opin Hematol. 2007;14:115-22.
52. Tefferi A. Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management. Am J Hematol. 2011;86:1017-26.
53. Barosi G, Rosti V, Bonetti E, et al. Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis. PLoS One. 2012;7:e35631. A landmark paper that supports the concept of early/prefibrotic PMF.
54. Kvasnicka HM, Thiele J. Bone marrow angiogenesis: methods of quantification and changes evolving in chronic myeloproliferative disorders. Histol Histopathol. 2004;19:1245-60.
55. Thiele J, Kvasnicka HM. Prefibrotic chronic idiopathic myelofibrosis-a diagnostic enigma? Acta Haematol. 2004;111:155-9.
56. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med. 2006;355:2452-66.
57. Lengfelder E, Hochhaus A, Kronawitter U, et al. Should a platelet limit of 600 × 10(9)/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages. Br J Haematol. 1998;100:15-23.
58. Regev A, Stark P, Blickstein D, et al. Thrombotic complications in essential thrombocythemia with relatively low platelet counts. Am J Hematol. 1997;56:168-72.
59. Sacchi S, Vinci G, Gugliotta L, et al. Diagnosis of essential thrombocythemia at platelet counts between 400 and 600x10(9)/L. Gruppo Italiano Malattie Mieloproliferative Croniche(GIMMC). Haematologica. 2000;85:492-5.
60. De Stefano V, Fiorini A, Rossi E, et al. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost. 2007;5:708-14.
61. Patel RK, Lea NC, Heneghan MA, et al. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology. 2006;130:2031-8.
62. Primignani M, Barosi G, Bergamaschi G, et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology. 2006;44:1528-34.
63. Smalberg JH, Murad SD, Braakman E, et al. Myeloproliferative disease in the pathogenesis and survival of Budd-Chiari syndrome. Haematologica. 2006;91:1712-3.
64. Colaizzo D, Amitrano L, Guardascione MA, et al. Outcome of patients with splanchnic venous thrombosis presenting without overt MPN: a role for the JAK2 V617F mutation re-evaluation. Thromb Res. 2013.
65. Donadini MP, Dentali F, Ageno W. Splanchnic vein thrombosis: new risk factors and management. Thromb Res. 2012;129 Suppl 1:S93-6.
66. Kiladjian JJ, Cervantes F, Leebeek FW, et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood. 2008;111:4922-9.
67. Kouroupi E, Kiladjian JJ, Chomienne C, et al. The JAK2 46/1 haplotype in splanchnic vein thrombosis. Blood. 2011;117:5777-8.
68. Villani L, Bergamaschi G, Primignani M, et al. JAK2 46/1 haplotype predisposes to splanchnic vein thrombosis-associated BCR-ABL negative classic myeloproliferative neoplasms. Leuk Res. 2012;36:e7-9.
69. Orazi A, Germing U. The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features. Leukemia. 2008;22:1308-19.
70. Shaw GR. Ringed sideroblasts with thrombocytosis: an uncommon mixed myelodysplastic/myeloproliferative disease of older adults. Br J Haematol. 2005;131:180-4.
71. Ceesay MM, Lea NC, Ingram W, et al. The JAK2 V617F mutation is rare in RARS but common in RARS-T. Leukemia. 2006;20:2060-1.
72. Hyjek E, Vardiman JW. Myelodysplastic/myeloproliferative neoplasms. Semin Diagn Pathol. 2011;28:283-97.
73. Malcovati L, Della Porta MG, Pietra D, et al. Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Blood. 2009;114:3538-45.
74. Schmitt-Graeff AH, Teo SS, Olschewski M, et al. JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica. 2008;93:34-40.
75. Atallah E, Nussenzveig R, Yin CC, et al. Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis. Leukemia. 2008;22:1295-8.
76. Kvasnicka HM, Thiele J. The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera. Semin Thromb Hemost. 2006;32:362-71.
77. Kvasnicka HM, Thiele J, Werden C, et al. Prognostic factors in idiopathic (primary) osteomyelofibrosis. Cancer. 1997;80:708-19.
78. Finazzi G, Carobbio A, Thiele J, et al. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. Leukemia. 2012;26:716-9.
79. Buxhofer-Ausch V, Gisslinger B, Stangl G, et al. Successful treatment sequence incorporating bevacizumab for therapy of polyneuropathy in two patients with POEMS syndrome. Leuk Res. 2012;36:e98-100.
80. Ejerblad E, Kvasnicka HM, Thiele J, et al. Diagnosis according to World Health Organization determines the long-term prognosis in patients with myeloproliferative neoplasms treated with anagrelide: results of a prospective long-term follow-up. Hematology. 2013;18:8-13. The first prospective study that provided evidence about significant differences in follow-up outcome between WHO-defined ET and early/prefibrotic PMF.
81. Gisslinger H, Gotic M, Holowiecki J, et al. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013;121:1720-8. An international prospective multicenter trial regarding WHO-defined ET and Anagrelide therapy.
82. Thiele J, Kvasnicka HM. Clinicopathological criteria for differential diagnosis of thrombocythemias in various myeloproliferative disorders. Semin Thromb Hemost. 2006;32:219-30. This paper highlights the problem associated with the classification of thrombocythemic MPDs.
83. Barosi G. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol. 1999;17:2954-70.
84. Johansson PL, Safai-Kutti S, Kutti J. An elevated venous haemoglobin concentration cannot be used as a surrogate marker for absolute erythrocytosis: a study of patients with polycythaemia vera and apparent polycythaemia. Br J Haematol. 2005;129:701-5.
85. Alvarez-Larran A, Ancochea A, Angona A, et al. Red cell mass measurement in patients with clinically suspected diagnosis of polycythemia vera or essential thrombocythemia. Haematologica. 2012;97:1704-7.
86. Cassinat B, Laguillier C, Gardin C, et al. Classification of myeloproliferative disorders in the JAK2 era: is there a role for red cell mass? Leukemia. 2008;22:452-3.
87. Silver RT, Chow W, Orazi A, et al. Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis. Blood. 2013. doi: 10.1182/blood-2013-06-508416. A comprehensive study regarding the current diagnostic criteria of PV and the value of bone marrow histology.
88. Barbui T, Thiele J, Gisslinger H, et al. Masked polycythemia vera (mPV): results of an international study. Am J Hematol. 2013. doi: 10.1002/ajh.23585.
89. Silver RT, Vandris K, Goldman JJ. Recombinant interferon-alpha may retard progression of early primary myelofibrosis: a preliminary report. Blood. 2011;117:6669-72.
90. Tefferi A. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol. 2013;88:507-16.
91. Mossuz P, Girodon F, Donnard M, et al. Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. Haematologica. 2004;89:1194-8.
92. Thiele J, Kvasnicka HM. Diagnostic impact of bone marrow histopathology in polycythemia vera (PV). Histol Histopathol. 2005;20:317-28.
93. Thiele J, Kvasnicka HM, Diehl V. Initial (latent) polycythemia vera with thrombocytosis mimicking essential thrombocythemia. Acta Haematol. 2005;113:213-9.
94. Barbui T, Thiele J, Passamonti F, et al. Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. Blood. 2012;119:2239-41.
95. Jantunen R, Juvonen E, Ikkala E, et al. Development of erythrocytosis in the course of essential thrombocythemia. Ann Hematol. 1999;78:219-22.
96. Gruppo Italiano Studio Policitemia. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med. 1995;123:656-64.
97. Carobbio A, Finazzi G, Antonioli E, et al. JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera. Exp Hematol. 2009;37:1016-21.
98. Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29:761-70.
99. Barosi G, Mesa RA, Thiele J, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia. 2008;22:437-8.